Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome, Inc. (IMNM) – Form 4 insider filing
Chief Technical Officer Philip Tsai was granted an employee stock option for 190,000 common shares on 29-Jul-2025 at an exercise price of $10.60. The options expire on 28-Jul-2035. No common shares were bought, sold or otherwise transferred in the filing; the entire award is reported as directly owned.
Vesting schedule: 25 % of the grant vests on 29-Jul-2026; the remaining 75 % vests in 36 equal monthly installments thereafter. Following this grant, Tsai beneficially owns 190,000 derivative securities (options) and no change to his non-derivative share count is disclosed.
The transaction is a routine equity incentive meant to align executive interests with shareholders. Dilution will only occur if the options are exercised at prices above $10.60.
Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded “A” (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.
Form 4 filing – Immunome, Inc. (IMNM) discloses that Chief Business Officer Kinney Horn received a new employee stock-option grant for 161,000 shares on 07/29/2025.
- Instrument: Non-qualified employee stock option giving the right to buy common stock at an exercise price of $10.60 per share.
- Vesting: 25 % vests on 07/29/2026; the remaining 75 % vests in equal monthly installments (1⁄36) thereafter, fully vesting by 07/29/2029.
- Expiration: 07/28/2035 (10-year term).
- Post-grant holdings: Horn now beneficially owns 161,000 derivative securities; no common shares were reported in Table I.
No shares were sold or disposed of, so the filing reflects compensation-related equity issuance rather than insider selling. The grant modestly increases the company’s fully-diluted share count and aligns the officer’s incentives with long-term shareholder value.
Form 4 snapshot: On 07/29/2025 Immunome (IMNM) granted Chief Scientific Officer Jack Higgins an employee stock option for 196,000 common shares at a strike price of $10.60. The option expires on 07/28/2035, giving a standard 10-year term.
Vesting schedule: 25 % of the award vests on 07/29/2026; the remaining 75 % vests in equal monthly installments over the next 36 months, completing vesting by mid-2029.
Table I shows no purchases or sales of non-derivative shares, so Higgins’ direct common-stock position is unchanged. After the grant he beneficially owns 196,000 derivative securities, all held directly.
Investor takeaway: The filing records routine executive compensation; no immediate cash outlay occurred and potential dilution is limited to the new option pool.